JP2018513682A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018513682A5 JP2018513682A5 JP2017552447A JP2017552447A JP2018513682A5 JP 2018513682 A5 JP2018513682 A5 JP 2018513682A5 JP 2017552447 A JP2017552447 A JP 2017552447A JP 2017552447 A JP2017552447 A JP 2017552447A JP 2018513682 A5 JP2018513682 A5 JP 2018513682A5
- Authority
- JP
- Japan
- Prior art keywords
- modified
- nucleotide sequence
- nucleotide
- nucleotides
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003729 nucleotide group Chemical group 0.000 claims description 105
- 238000000034 method Methods 0.000 claims description 101
- 239000002773 nucleotide Substances 0.000 claims description 76
- 210000004027 cell Anatomy 0.000 claims description 35
- 229920001184 polypeptide Polymers 0.000 claims description 35
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 35
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 35
- 108020004707 nucleic acids Proteins 0.000 claims description 24
- 102000039446 nucleic acids Human genes 0.000 claims description 24
- 150000007523 nucleic acids Chemical class 0.000 claims description 24
- 108090000623 proteins and genes Proteins 0.000 claims description 22
- 108020004414 DNA Proteins 0.000 claims description 14
- 230000004048 modification Effects 0.000 claims description 13
- 238000012986 modification Methods 0.000 claims description 13
- 230000033228 biological regulation Effects 0.000 claims description 8
- 125000000548 ribosyl group Chemical group C1([C@H](O)[C@H](O)[C@H](O1)CO)* 0.000 claims description 8
- 108091033409 CRISPR Proteins 0.000 claims description 6
- 230000035772 mutation Effects 0.000 claims description 6
- 210000000130 stem cell Anatomy 0.000 claims description 6
- 108020005004 Guide RNA Proteins 0.000 claims description 5
- 230000000694 effects Effects 0.000 claims description 5
- 108020004999 messenger RNA Proteins 0.000 claims description 5
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 4
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 4
- 210000002865 immune cell Anatomy 0.000 claims description 4
- 230000006780 non-homologous end joining Effects 0.000 claims description 4
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 claims description 4
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims description 4
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 claims description 4
- 238000010354 CRISPR gene editing Methods 0.000 claims description 3
- 230000000295 complement effect Effects 0.000 claims description 3
- 239000013604 expression vector Substances 0.000 claims description 3
- 239000012634 fragment Substances 0.000 claims description 3
- 102000004169 proteins and genes Human genes 0.000 claims description 3
- 238000003259 recombinant expression Methods 0.000 claims description 3
- 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 claims description 2
- 108010042407 Endonucleases Proteins 0.000 claims description 2
- 102000004533 Endonucleases Human genes 0.000 claims description 2
- 241000233866 Fungi Species 0.000 claims description 2
- 108091027544 Subgenomic mRNA Proteins 0.000 claims description 2
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 2
- 230000004913 activation Effects 0.000 claims description 2
- 230000002950 deficient Effects 0.000 claims description 2
- 230000034431 double-strand break repair via homologous recombination Effects 0.000 claims description 2
- 238000004520 electroporation Methods 0.000 claims description 2
- 230000014509 gene expression Effects 0.000 claims description 2
- 238000010362 genome editing Methods 0.000 claims description 2
- 230000003394 haemopoietic effect Effects 0.000 claims description 2
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims description 2
- 230000001939 inductive effect Effects 0.000 claims description 2
- 230000005764 inhibitory process Effects 0.000 claims description 2
- 210000002901 mesenchymal stem cell Anatomy 0.000 claims description 2
- 210000001616 monocyte Anatomy 0.000 claims description 2
- 210000000822 natural killer cell Anatomy 0.000 claims description 2
- 210000001178 neural stem cell Anatomy 0.000 claims description 2
- 229940046166 oligodeoxynucleotide Drugs 0.000 claims description 2
- 210000000056 organ Anatomy 0.000 claims description 2
- 239000002243 precursor Substances 0.000 claims description 2
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 claims description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 208000035475 disorder Diseases 0.000 description 6
- 208000026350 Inborn Genetic disease Diseases 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000016361 genetic disease Diseases 0.000 description 3
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 208000019693 Lung disease Diseases 0.000 description 2
- 208000015294 blood coagulation disease Diseases 0.000 description 2
- 208000017169 kidney disease Diseases 0.000 description 2
- 208000019423 liver disease Diseases 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 206010003805 Autism Diseases 0.000 description 1
- 208000020706 Autistic disease Diseases 0.000 description 1
- 201000003883 Cystic fibrosis Diseases 0.000 description 1
- 208000001914 Fragile X syndrome Diseases 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 208000037357 HIV infectious disease Diseases 0.000 description 1
- 208000031220 Hemophilia Diseases 0.000 description 1
- 208000009292 Hemophilia A Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 102000029797 Prion Human genes 0.000 description 1
- 108091000054 Prion Proteins 0.000 description 1
- 208000012827 T-B+ severe combined immunodeficiency due to gamma chain deficiency Diseases 0.000 description 1
- 208000002903 Thalassemia Diseases 0.000 description 1
- 208000023940 X-Linked Combined Immunodeficiency disease Diseases 0.000 description 1
- 201000007146 X-linked severe combined immunodeficiency Diseases 0.000 description 1
- 206010064930 age-related macular degeneration Diseases 0.000 description 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 206010013663 drug dependence Diseases 0.000 description 1
- 208000030533 eye disease Diseases 0.000 description 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 208000002780 macular degeneration Diseases 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 208000007056 sickle cell anemia Diseases 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 239000000277 virosome Substances 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562143729P | 2015-04-06 | 2015-04-06 | |
| US62/143,729 | 2015-04-06 | ||
| US201562160545P | 2015-05-12 | 2015-05-12 | |
| US62/160,545 | 2015-05-12 | ||
| PCT/US2016/026028 WO2016164356A1 (en) | 2015-04-06 | 2016-04-05 | Chemically modified guide rnas for crispr/cas-mediated gene regulation |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018513682A JP2018513682A (ja) | 2018-05-31 |
| JP2018513682A5 true JP2018513682A5 (https=) | 2019-05-16 |
| JP6873911B2 JP6873911B2 (ja) | 2021-05-19 |
Family
ID=55910340
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017552447A Active JP6873911B2 (ja) | 2015-04-06 | 2016-04-05 | 初代細胞において標的核酸の遺伝子調節を誘導するためにインビトロで行う方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (5) | US11306309B2 (https=) |
| EP (1) | EP3280803B1 (https=) |
| JP (1) | JP6873911B2 (https=) |
| KR (2) | KR102648489B1 (https=) |
| CN (2) | CN107787367B (https=) |
| AU (2) | AU2016246450B2 (https=) |
| CA (1) | CA2981715A1 (https=) |
| ES (1) | ES2884838T3 (https=) |
| WO (1) | WO2016164356A1 (https=) |
Families Citing this family (161)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6261500B2 (ja) | 2011-07-22 | 2018-01-17 | プレジデント アンド フェローズ オブ ハーバード カレッジ | ヌクレアーゼ切断特異性の評価および改善 |
| US20150044192A1 (en) | 2013-08-09 | 2015-02-12 | President And Fellows Of Harvard College | Methods for identifying a target site of a cas9 nuclease |
| US9359599B2 (en) | 2013-08-22 | 2016-06-07 | President And Fellows Of Harvard College | Engineered transcription activator-like effector (TALE) domains and uses thereof |
| US9526784B2 (en) | 2013-09-06 | 2016-12-27 | President And Fellows Of Harvard College | Delivery system for functional nucleases |
| US9388430B2 (en) | 2013-09-06 | 2016-07-12 | President And Fellows Of Harvard College | Cas9-recombinase fusion proteins and uses thereof |
| US9340799B2 (en) | 2013-09-06 | 2016-05-17 | President And Fellows Of Harvard College | MRNA-sensing switchable gRNAs |
| US20150165054A1 (en) | 2013-12-12 | 2015-06-18 | President And Fellows Of Harvard College | Methods for correcting caspase-9 point mutations |
| WO2015153789A1 (en) * | 2014-04-01 | 2015-10-08 | Editas Medicine, Inc. | Crispr/cas-related methods and compositions for treating herpes simplex virus type 1 (hsv-1) |
| WO2016022363A2 (en) | 2014-07-30 | 2016-02-11 | President And Fellows Of Harvard College | Cas9 proteins including ligand-dependent inteins |
| US10040048B1 (en) | 2014-09-25 | 2018-08-07 | Synthego Corporation | Automated modular system and method for production of biopolymers |
| US10900034B2 (en) | 2014-12-03 | 2021-01-26 | Agilent Technologies, Inc. | Guide RNA with chemical modifications |
| CN112877327B (zh) | 2014-12-18 | 2024-11-22 | 综合基因技术公司 | 基于crispr的组合物和使用方法 |
| WO2016135559A2 (en) | 2015-02-23 | 2016-09-01 | Crispr Therapeutics Ag | Materials and methods for treatment of human genetic diseases including hemoglobinopathies |
| AU2016225178B2 (en) | 2015-02-23 | 2022-05-05 | Crispr Therapeutics Ag | Materials and methods for treatment of hemoglobinopathies |
| EP3280803B1 (en) * | 2015-04-06 | 2021-05-26 | The Board of Trustees of the Leland Stanford Junior University | Chemically modified guide rnas for crispr/cas-mediated gene regulation |
| US11279928B2 (en) | 2015-06-29 | 2022-03-22 | Massachusetts Institute Of Technology | Compositions comprising nucleic acids and methods of using the same |
| WO2017053729A1 (en) | 2015-09-25 | 2017-03-30 | The Board Of Trustees Of The Leland Stanford Junior University | Nuclease-mediated genome editing of primary cells and enrichment thereof |
| EP3159407A1 (en) * | 2015-10-23 | 2017-04-26 | Silence Therapeutics (London) Ltd | Guide rnas, methods and uses |
| JP7109784B2 (ja) | 2015-10-23 | 2022-08-01 | プレジデント アンド フェローズ オブ ハーバード カレッジ | 遺伝子編集のための進化したＣａｓ９蛋白質 |
| ES2942309T3 (es) | 2015-11-04 | 2023-05-31 | Vertex Pharma | Materiales y métodos para el tratamiento de hemoglobinopatías |
| US11518994B2 (en) | 2016-01-30 | 2022-12-06 | Bonac Corporation | Artificial single guide RNA and use thereof |
| US11845933B2 (en) | 2016-02-03 | 2023-12-19 | Massachusetts Institute Of Technology | Structure-guided chemical modification of guide RNA and its applications |
| KR102547316B1 (ko) | 2016-08-03 | 2023-06-23 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 아데노신 핵염기 편집제 및 그의 용도 |
| US11661590B2 (en) | 2016-08-09 | 2023-05-30 | President And Fellows Of Harvard College | Programmable CAS9-recombinase fusion proteins and uses thereof |
| KR101710026B1 (ko) | 2016-08-10 | 2017-02-27 | 주식회사 무진메디 | Cas9 단백질 및 가이드 RNA의 혼성체를 함유하는 나노 리포좀 전달체 조성물 |
| BR112019002779A2 (pt) * | 2016-08-12 | 2019-05-14 | Toolgen Incorporated | elemento imunorregulador manipulado e imunidade alterada por este |
| JP7308143B2 (ja) | 2016-08-19 | 2023-07-13 | ホワイトヘッド・インスティテュート・フォー・バイオメディカル・リサーチ | Ｄｎａメチル化の編集方法 |
| US11542509B2 (en) | 2016-08-24 | 2023-01-03 | President And Fellows Of Harvard College | Incorporation of unnatural amino acids into proteins using base editing |
| JP7682604B2 (ja) | 2016-09-07 | 2025-05-26 | フラッグシップ パイオニアリング イノベーションズ ブイ， インコーポレイテッド | 遺伝子発現をモジュレートするための方法および組成物 |
| US11242542B2 (en) | 2016-10-07 | 2022-02-08 | Integrated Dna Technologies, Inc. | S. pyogenes Cas9 mutant genes and polypeptides encoded by same |
| CN118726313A (zh) | 2016-10-07 | 2024-10-01 | 综合Dna技术公司 | 化脓链球菌cas9突变基因和由其编码的多肽 |
| EP3526320A1 (en) | 2016-10-14 | 2019-08-21 | President and Fellows of Harvard College | Aav delivery of nucleobase editors |
| WO2018098383A1 (en) | 2016-11-22 | 2018-05-31 | Integrated Dna Technologies, Inc. | Crispr/cpf1 systems and methods |
| AU2017374044B2 (en) * | 2016-12-08 | 2023-11-30 | Intellia Therapeutics, Inc. | Modified guide RNAs |
| WO2018111944A1 (en) | 2016-12-12 | 2018-06-21 | Whitehead Institute For Biomedical Research | Regulation of transcription through ctcf loop anchors |
| WO2018111947A1 (en) | 2016-12-12 | 2018-06-21 | Integrated Dna Technologies, Inc. | Genome editing enhancement |
| EP4286523A3 (en) | 2016-12-20 | 2024-03-20 | Bristol-Myers Squibb Company | Methods for increasing the efficiency of homology directed repair (hdr) in the cellular genome |
| AU2017379073B2 (en) * | 2016-12-22 | 2023-12-14 | Intellia Therapeutics, Inc. | Compositions and methods for treating alpha-1 antitrypsin deficiency |
| WO2018119359A1 (en) | 2016-12-23 | 2018-06-28 | President And Fellows Of Harvard College | Editing of ccr5 receptor gene to protect against hiv infection |
| AU2017388753A1 (en) * | 2016-12-30 | 2019-07-11 | Editas Medicine, Inc. | Synthetic guide molecules, compositions and methods relating thereto |
| JOP20190166A1 (ar) * | 2017-01-05 | 2019-07-02 | Univ Texas | استراتيجية مثلى من أجل تعديلات تخطي إكسون باستخدام crispr/cas9 مع متواليات توجيه ثلاثي |
| EP3565891B1 (en) | 2017-01-09 | 2023-04-12 | Whitehead Institute for Biomedical Research | Methods of altering gene expression by perturbing transcription factor multimers that structure regulatory loops |
| TW201839136A (zh) | 2017-02-06 | 2018-11-01 | 瑞士商諾華公司 | 治療血色素異常症之組合物及方法 |
| AU2018221730B2 (en) * | 2017-02-15 | 2024-06-20 | Novo Nordisk A/S | Donor repair templates multiplex genome editing |
| US20200095579A1 (en) * | 2017-02-22 | 2020-03-26 | Crispr Therapeutics Ag | Materials and methods for treatment of merosin-deficient cogenital muscular dystrophy (mdcmd) and other laminin, alpha 2 (lama2) gene related conditions or disorders |
| EP3585897A1 (en) * | 2017-02-22 | 2020-01-01 | CRISPR Therapeutics AG | Materials and methods for treatment of dystrophic epidermolysis bullosa (deb) and other collagen type vii alpha 1 chain (col7a1) gene related conditions or disorders |
| SG11201907870VA (en) | 2017-02-28 | 2019-09-27 | Vor Biopharma Inc | Compositions and methods for inhibition of lineage specific proteins |
| EP3592853A1 (en) | 2017-03-09 | 2020-01-15 | President and Fellows of Harvard College | Suppression of pain by gene editing |
| JP2020510038A (ja) | 2017-03-09 | 2020-04-02 | プレジデント アンド フェローズ オブ ハーバード カレッジ | がんワクチン |
| JP2020510439A (ja) | 2017-03-10 | 2020-04-09 | プレジデント アンド フェローズ オブ ハーバード カレッジ | シトシンからグアニンへの塩基編集因子 |
| WO2018175480A1 (en) * | 2017-03-20 | 2018-09-27 | The Research Foundation For The State University Of New York | Methods of inhibiting fungal ceramide synthase for treatment of cryptococcus neoformans infection |
| CA3057192A1 (en) | 2017-03-23 | 2018-09-27 | President And Fellows Of Harvard College | Nucleobase editors comprising nucleic acid programmable dna binding proteins |
| JP2020515258A (ja) * | 2017-03-31 | 2020-05-28 | アジェノビア コーポレーション | 抗ウイルス治療剤 |
| JP7235391B2 (ja) | 2017-05-08 | 2023-03-08 | ツールゲン インコーポレイテッド | 人工的に操作された免疫細胞 |
| WO2018209320A1 (en) | 2017-05-12 | 2018-11-15 | President And Fellows Of Harvard College | Aptazyme-embedded guide rnas for use with crispr-cas9 in genome editing and transcriptional activation |
| US11166985B2 (en) | 2017-05-12 | 2021-11-09 | Crispr Therapeutics Ag | Materials and methods for engineering cells and uses thereof in immuno-oncology |
| MX2019013514A (es) | 2017-05-12 | 2020-01-20 | Crispr Therapeutics Ag | Materiales y metodos para modificar celulas por ingenieria genetica y usos de los mismos en inmunooncologia. |
| US11866726B2 (en) | 2017-07-14 | 2024-01-09 | Editas Medicine, Inc. | Systems and methods for targeted integration and genome editing and detection thereof using integrated priming sites |
| WO2019023680A1 (en) | 2017-07-28 | 2019-01-31 | President And Fellows Of Harvard College | METHODS AND COMPOSITIONS FOR EVOLUTION OF BASIC EDITORS USING PHAGE-ASSISTED CONTINUOUS EVOLUTION (PACE) |
| EP3676376B1 (en) | 2017-08-30 | 2025-01-15 | President and Fellows of Harvard College | High efficiency base editors comprising gam |
| US20190076814A1 (en) | 2017-09-11 | 2019-03-14 | Synthego Corporation | Biopolymer synthesis system and method |
| TW201920661A (zh) * | 2017-09-18 | 2019-06-01 | 大陸商博雅輯因（北京）生物科技有限公司 | 一種基因編輯t細胞及其用途 |
| KR20250107288A (ko) | 2017-10-16 | 2025-07-11 | 더 브로드 인스티튜트, 인코퍼레이티드 | 아데노신 염기 편집제의 용도 |
| CN111629747A (zh) | 2017-12-05 | 2020-09-04 | 沃泰克斯药物股份有限公司 | Crispr-cas9修饰的cd34+人血色素干细胞和祖细胞及其用途 |
| WO2019118949A1 (en) | 2017-12-15 | 2019-06-20 | The Broad Institute, Inc. | Systems and methods for predicting repair outcomes in genetic engineering |
| WO2019143077A1 (ko) * | 2018-01-22 | 2019-07-25 | 경상대학교산학협력단 | 식물체에서 상동재조합 기반의 유전자 편집 효율을 증가시키는 방법 |
| WO2019147743A1 (en) * | 2018-01-26 | 2019-08-01 | Massachusetts Institute Of Technology | Structure-guided chemical modification of guide rna and its applications |
| US11268077B2 (en) | 2018-02-05 | 2022-03-08 | Vertex Pharmaceuticals Incorporated | Materials and methods for treatment of hemoglobinopathies |
| MA51787A (fr) | 2018-02-05 | 2020-12-16 | Vertex Pharma | Substances et méthodes de traitement d'hémoglobinopathies |
| CN110229814B (zh) * | 2018-03-06 | 2025-11-14 | 中国科学院动物研究所 | 改进的向导rna |
| JP7469806B2 (ja) * | 2018-03-29 | 2024-04-17 | 学校法人自治医科大学 | ゲノム編集方法、組成物、細胞、細胞製剤、及び細胞製剤の製造方法 |
| JP2021522188A (ja) * | 2018-04-18 | 2021-08-30 | イエール ユニバーシティ | 内因性遺伝子活性化を用いる多重腫瘍ワクチン接種のための組成物および方法 |
| US12227763B2 (en) | 2018-05-11 | 2025-02-18 | Crispr Therapeutics Ag | Methods and compositions for treating cancer |
| KR20210045360A (ko) | 2018-05-16 | 2021-04-26 | 신테고 코포레이션 | 가이드 rna 설계 및 사용을 위한 방법 및 시스템 |
| EP3797160A1 (en) | 2018-05-23 | 2021-03-31 | The Broad Institute Inc. | Base editors and uses thereof |
| CN108624592B (zh) * | 2018-05-24 | 2021-08-17 | 苏州大学张家港工业技术研究院 | 针对DJ-1基因编辑的sgRNA筛选及其载体与应用 |
| EP3802818A4 (en) * | 2018-05-25 | 2022-03-02 | New York Institute of Technology | Method and system for use in direct sequencing of rna |
| WO2019229722A1 (en) * | 2018-06-01 | 2019-12-05 | Avectas Limited | Cell engineering platform |
| WO2019237069A1 (en) * | 2018-06-08 | 2019-12-12 | Intellia Therapeutics, Inc. | Modified guide rnas for gene editing |
| CN110616187B (zh) * | 2018-06-20 | 2021-12-03 | 西安桑尼赛尔生物医药有限公司 | CRISPR-Cas9高效敲入嵌合抗原受体基因到T细胞特定基因组位点的方法及应用 |
| CN110616233B (zh) * | 2018-06-20 | 2022-02-22 | 西安桑尼赛尔生物医药有限公司 | CRISPR-Cas9高效敲除原代T细胞基因的方法及其应用 |
| EP3823633A4 (en) | 2018-06-29 | 2023-05-03 | Editas Medicine, Inc. | SYNTHETIC LEAD MOLECULES, COMPOSITIONS AND METHODS RELATED THERETO |
| US12522807B2 (en) | 2018-07-09 | 2026-01-13 | The Broad Institute, Inc. | RNA programmable epigenetic RNA modifiers and uses thereof |
| CA3110837A1 (en) * | 2018-08-28 | 2020-03-05 | Vor Biopharma Inc. | Genetically engineered hematopoietic stem cells and uses thereof |
| US12097239B2 (en) | 2018-09-21 | 2024-09-24 | President And Fellows Of Harvard College | Methods and compositions for treating diabetes, and methods for enriching MRNA coding for secreted proteins |
| WO2020068643A1 (en) * | 2018-09-25 | 2020-04-02 | Excision Biotherapeutics, Inc. | CRISPRs WITH IMPROVED SPECIFICITY |
| KR102126573B1 (ko) | 2018-10-18 | 2020-06-26 | 대한민국 | CRISPR-Cas9 시스템을 이용한 유색고약버섯의 리그닌 분해효소의 유전자 편집방법 및 이의 용도 |
| CN111088253A (zh) * | 2018-10-24 | 2020-05-01 | 广州鼓润医疗科技有限公司 | 针对hbb-28地中海贫血基因的crispr单碱基供体修复体系 |
| WO2020092453A1 (en) | 2018-10-29 | 2020-05-07 | The Broad Institute, Inc. | Nucleobase editors comprising geocas9 and uses thereof |
| CN111254164A (zh) * | 2018-11-30 | 2020-06-09 | 中国科学院大连化学物理研究所 | 一种快速建立crispr基因编辑肝癌细胞株的方法及细胞株 |
| CN111321171A (zh) * | 2018-12-14 | 2020-06-23 | 江苏集萃药康生物科技有限公司 | 一种应用CRISPR/Cas9介导ES打靶技术制备基因打靶动物模型的方法 |
| CN109652440A (zh) * | 2018-12-28 | 2019-04-19 | 北京市农林科学院 | VQRn-Cas9&PmCDA1&UGI碱基编辑系统在植物基因编辑中的应用 |
| US12351837B2 (en) | 2019-01-23 | 2025-07-08 | The Broad Institute, Inc. | Supernegatively charged proteins and uses thereof |
| CN110157695A (zh) * | 2019-01-25 | 2019-08-23 | 南昌大学 | 一种植物RNA m5C甲基化修饰的系统及方法 |
| JP7657726B2 (ja) | 2019-03-19 | 2025-04-07 | ザ ブロード インスティテュート，インコーポレーテッド | 編集ヌクレオチド配列を編集するための方法および組成物 |
| US12473543B2 (en) | 2019-04-17 | 2025-11-18 | The Broad Institute, Inc. | Adenine base editors with reduced off-target effects |
| US20220249558A1 (en) | 2019-04-30 | 2022-08-11 | Crispr Therapeutics Ag | Allogeneic cell therapy of b cell malignancies using genetically engineered t cells targeting cd19 |
| CN114423865A (zh) | 2019-05-23 | 2022-04-29 | Vor生物制药股份有限公司 | Cd33修饰的组合物和方法 |
| CN110283838B (zh) * | 2019-06-27 | 2022-03-25 | 安徽省农业科学院水稻研究所 | 一种高剪切效率ScCas9基因及其应用 |
| US20220315938A1 (en) * | 2019-08-09 | 2022-10-06 | Regents Of The University Of Minnesota | AUGMENTED sgRNAS AND METHODS FOR THEIR USE TO ENHANCE SOMATIC AND GERMLINE PLANT GENOME ENGINEERING |
| AU2020336211A1 (en) | 2019-08-28 | 2022-03-10 | Vor Biopharma Inc. | Compositions and methods for CD123 modification |
| US20220290160A1 (en) | 2019-08-28 | 2022-09-15 | Vor Biopharma Inc. | Compositions and methods for cll1 modification |
| CN114729376A (zh) | 2019-09-23 | 2022-07-08 | 欧米茄治疗公司 | 用于调节肝细胞核因子4α(HNF4α)基因表达的组合物和方法 |
| AU2020358863A1 (en) | 2019-10-03 | 2022-05-12 | Celyntra Therapeutics Sa | CRISPR systems with engineered dual guide nucleic acids |
| US12435330B2 (en) | 2019-10-10 | 2025-10-07 | The Broad Institute, Inc. | Methods and compositions for prime editing RNA |
| US20230028445A1 (en) * | 2019-10-11 | 2023-01-26 | Black Hawk Genomics, Llc | Identification of genomic structural variants using long-read sequencing |
| CN115279898A (zh) | 2019-10-23 | 2022-11-01 | 成对植物服务股份有限公司 | 用于植物中rna模板化编辑的组合物和方法 |
| CA3160186A1 (en) * | 2019-11-05 | 2021-05-14 | Pairwise Plants Services, Inc. | Compositions and methods for rna-encoded dna-replacement of alleles |
| US12521451B2 (en) | 2019-11-08 | 2026-01-13 | Regeneron Pharmaceuticals, Inc. | CRISPR and AAV strategies for x-linked juvenile retinoschisis therapy |
| MX2022006950A (es) * | 2019-12-11 | 2022-11-07 | Intellia Therapeutics Inc | Arn guía modificados para edición de genes. |
| IL271656A (en) | 2019-12-22 | 2021-06-30 | Yeda Res & Dev | System and methods for identifying cells that have undergone genome editing |
| DE112021002672T5 (de) | 2020-05-08 | 2023-04-13 | President And Fellows Of Harvard College | Vefahren und zusammensetzungen zum gleichzeitigen editieren beider stränge einer doppelsträngigen nukleotid-zielsequenz |
| EP4189073A1 (en) * | 2020-08-03 | 2023-06-07 | The Board of Trustees of the Leland Stanford Junior University | Gene correction for scid-x1 in long-term hematopoietic stem cells |
| CN112111507B (zh) * | 2020-08-10 | 2022-08-23 | 江苏大学 | 一种灰树花CRISPR-Cas9基因编辑系统、方法及应用 |
| CN112266911B (zh) * | 2020-08-27 | 2022-07-22 | 清华大学 | 核酸分子 |
| US20240110189A1 (en) | 2020-08-28 | 2024-04-04 | Vor Biopharma Inc. | Compositions and methods for cll1 modification |
| US20240238344A1 (en) | 2020-08-28 | 2024-07-18 | Vor Biopharma Inc. | Compositions and methods for cd123 modification |
| JP2023541457A (ja) | 2020-09-14 | 2023-10-02 | ブイオーアール バイオファーマ インコーポレーテッド | Ｃｄ３８修飾のための化合物および方法 |
| WO2022056459A1 (en) | 2020-09-14 | 2022-03-17 | Vor Biopharma, Inc. | Compositions and methods for cd5 modification |
| WO2022061115A1 (en) | 2020-09-18 | 2022-03-24 | Vor Biopharma Inc. | Compositions and methods for cd7 modification |
| WO2022067240A1 (en) | 2020-09-28 | 2022-03-31 | Vor Biopharma, Inc. | Compositions and methods for cd6 modification |
| US20230364146A1 (en) | 2020-09-30 | 2023-11-16 | Vor Biopharma Inc. | Compositions and methods for cd30 gene modification |
| CN112126661B (zh) * | 2020-09-30 | 2022-07-22 | 上海中医药大学 | 一种高效敲除nk细胞中tigit基因的方法 |
| US20230357798A1 (en) * | 2020-10-12 | 2023-11-09 | The Board Of Trustees Of The Leland Stanford Junior University | Gene correction for x-cgd in hematopoietic stem and progenitor cells |
| CA3199623A1 (en) | 2020-10-27 | 2022-05-05 | Vor Biopharma Inc. | Compositions and methods for treating hematopoietic malignancy |
| WO2022094245A1 (en) | 2020-10-30 | 2022-05-05 | Vor Biopharma, Inc. | Compositions and methods for bcma modification |
| CN112553195B (zh) * | 2020-11-05 | 2022-04-05 | 南方医科大学 | 一种用于CRISPR-Cas9定点突变编辑DNMT1基因的试剂及其应用 |
| JP2023550355A (ja) | 2020-11-13 | 2023-12-01 | ブイオーアール バイオファーマ インコーポレーテッド | キメラ抗原受容体を発現する遺伝子操作された細胞に関連する方法および組成物 |
| WO2022147347A1 (en) | 2020-12-31 | 2022-07-07 | Vor Biopharma Inc. | Compositions and methods for cd34 gene modification |
| EP4298212A4 (en) | 2021-02-25 | 2026-04-15 | Celyntra Therapeutics Sa | Compositions and methods for targeting, editing, or modifying genes |
| BR112023018157A2 (pt) * | 2021-03-09 | 2023-10-31 | Illumina Inc | Análise de expressão de variantes codificantes de proteína em células |
| US20240200059A1 (en) | 2021-04-09 | 2024-06-20 | Vor Biopharma Inc. | Photocleavable guide rnas and methods of use thereof |
| EP4419672A2 (en) | 2021-06-01 | 2024-08-28 | Artisan Development Labs, Inc. | Compositions and methods for targeting, editing, or modifying genes |
| EP4355879A4 (en) | 2021-06-14 | 2025-07-23 | Kamau Therapeutics Inc | METHODS FOR GENETIC MODIFICATION OF HEMATOPOIETIC STEM AND PROGENITOR CELLS FOR ERYTHROCYTE-SPECIFIC EXPRESSION OF THERAPEUTIC PROTEINS |
| EP4370676A2 (en) | 2021-06-18 | 2024-05-22 | Artisan Development Labs, Inc. | Compositions and methods for targeting, editing or modifying human genes |
| US20240384304A1 (en) | 2021-07-06 | 2024-11-21 | Vor Biopharma Inc. | Inhibitor oligonucleotides and methods of use thereof |
| AU2022324093A1 (en) | 2021-08-02 | 2024-02-08 | Vor Biopharma Inc. | Compositions and methods for gene modification |
| JP2024534945A (ja) * | 2021-09-10 | 2024-09-26 | アジレント・テクノロジーズ・インク | 化学修飾を有するプライム編集のためのガイドｒｎａ |
| WO2023043856A1 (en) * | 2021-09-14 | 2023-03-23 | Agilent Technologies, Inc. | Methods for using guide rnas with chemical modifications |
| US20240417755A1 (en) | 2021-09-27 | 2024-12-19 | Vor Biopharma Inc. | Fusion polypeptides for genetic editing and methods of use thereof |
| EP4413146A2 (en) * | 2021-10-05 | 2024-08-14 | The Board of Trustees of the Leland Stanford Junior University | Treatment of polycythemia vera via crispr/aav6 genome editing |
| CA3236152A1 (en) | 2021-11-09 | 2023-05-19 | Vor Biopharma Inc. | Compositions and methods for erm2 modification |
| CA3242790A1 (en) * | 2021-12-30 | 2023-07-06 | Cue Health Inc. | COMPOSITIONS AND METHODS OF ISOTHERMAL AMPLIFICATION OF NUCLEIC ACIDS |
| WO2023155924A1 (en) * | 2022-02-21 | 2023-08-24 | Huidagene Therapeutics Co., Ltd. | Guide rna and uses thereof |
| US20250179531A1 (en) | 2022-02-25 | 2025-06-05 | Vor Biopharma Inc. | Compositions and methods for homology-directed repair gene modification |
| EP4486881A1 (en) | 2022-03-01 | 2025-01-08 | Celyntra Therapeutics SA | Composition and methods for transgene insertion |
| WO2023185697A2 (en) | 2022-03-29 | 2023-10-05 | Accuredit Therapeutics (Suzhou) Co., Ltd. | Compositions and methods for treatment of transthyretin amyloidosis |
| US20250295695A1 (en) | 2022-04-04 | 2025-09-25 | Vor Biopharma Inc. | Compositions and methods for mediating epitope engineering |
| EP4526884A2 (en) | 2022-05-20 | 2025-03-26 | Artisan Development Labs, Inc. | Systems and methods for assessing risk of genome editing events |
| WO2024015925A2 (en) | 2022-07-13 | 2024-01-18 | Vor Biopharma Inc. | Compositions and methods for artificial protospacer adjacent motif (pam) generation |
| EP4590820A2 (en) | 2022-09-22 | 2025-07-30 | Accuredit Therapeutics (Suzhou) Co., Ltd. | Compositions and methods for treatment of hypercholesterolemia and/or cardiovascular disease |
| WO2024062138A1 (en) | 2022-09-23 | 2024-03-28 | Mnemo Therapeutics | Immune cells comprising a modified suv39h1 gene |
| WO2024073751A1 (en) | 2022-09-29 | 2024-04-04 | Vor Biopharma Inc. | Methods and compositions for gene modification and enrichment |
| KR20250153183A (ko) | 2022-12-19 | 2025-10-24 | 카마우 테라퓨틱스, 인크. | P53 결합 단백질인 53bp1의 개선된 펩타이드 저해제 |
| WO2024168312A1 (en) | 2023-02-09 | 2024-08-15 | Vor Biopharma Inc. | Methods for treating hematopoietic malignancy |
| WO2024193704A1 (en) * | 2023-03-22 | 2024-09-26 | Huidagene Therapeutics Co., Ltd. | Guide nucleic acids targeting dmd and uses thereof |
| IL324634A (en) | 2023-05-15 | 2026-01-01 | Nchroma Bio Inc | Compositions and methods for epigenetic regulation of hbv gene expression |
| WO2025030010A1 (en) | 2023-08-01 | 2025-02-06 | Vor Biopharma Inc. | Compositions comprising genetically engineered hematopoietic stem cells and methods of use thereof |
| WO2025177303A1 (en) * | 2024-02-19 | 2025-08-28 | Micro Crispr Pvt Ltd. | Crispr-mediated gene editing to induce fetal hemoglobin |
| CN118813625B (zh) * | 2024-06-17 | 2025-08-26 | 天海元祺生物科技(天津)有限公司 | 高度靶向人类HLA-A基因的sgRNA及应用 |
| WO2026020120A1 (en) * | 2024-07-19 | 2026-01-22 | University Of Massachusetts | Increasing cas9 genome editing fidelity through attenuation of guide rna watson-crick base pairing potential |
Family Cites Families (162)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5132418A (en) | 1980-02-29 | 1992-07-21 | University Patents, Inc. | Process for preparing polynucleotides |
| US4500707A (en) | 1980-02-29 | 1985-02-19 | University Patents, Inc. | Nucleosides useful in the preparation of polynucleotides |
| US4458066A (en) | 1980-02-29 | 1984-07-03 | University Patents, Inc. | Process for preparing polynucleotides |
| US4668777A (en) | 1981-03-27 | 1987-05-26 | University Patents, Inc. | Phosphoramidite nucleoside compounds |
| US4973679A (en) | 1981-03-27 | 1990-11-27 | University Patents, Inc. | Process for oligonucleo tide synthesis using phosphormidite intermediates |
| US4373071A (en) | 1981-04-30 | 1983-02-08 | City Of Hope Research Institute | Solid-phase synthesis of polynucleotides |
| US5153319A (en) | 1986-03-31 | 1992-10-06 | University Patents, Inc. | Process for preparing polynucleotides |
| US5262530A (en) | 1988-12-21 | 1993-11-16 | Applied Biosystems, Inc. | Automated system for polynucleotide synthesis and purification |
| US5047524A (en) | 1988-12-21 | 1991-09-10 | Applied Biosystems, Inc. | Automated system for polynucleotide synthesis and purification |
| US5032401A (en) | 1989-06-15 | 1991-07-16 | Alpha Beta Technology | Glucan drug delivery system and adjuvant |
| US5700642A (en) | 1995-05-22 | 1997-12-23 | Sri International | Oligonucleotide sizing using immobilized cleavable primers |
| US7371580B2 (en) | 2001-08-24 | 2008-05-13 | Agilent Technologies, Inc. | Use of unstructured nucleic acids in assaying nucleic acid molecules |
| US7682828B2 (en) | 2003-11-26 | 2010-03-23 | Whitehead Institute For Biomedical Research | Methods for reprogramming somatic cells |
| US20070122906A1 (en) | 2003-12-29 | 2007-05-31 | Allan Mishra | Method of culturing cells |
| US7740861B2 (en) | 2004-06-16 | 2010-06-22 | University Of Massachusetts | Drug delivery product and methods |
| US8278104B2 (en) | 2005-12-13 | 2012-10-02 | Kyoto University | Induced pluripotent stem cells produced with Oct3/4, Klf4 and Sox2 |
| WO2008141248A2 (en) | 2007-05-10 | 2008-11-20 | Agilent Technologies, Inc. | Thiocarbon-protecting groups for rna synthesis |
| JP5558097B2 (ja) | 2007-12-10 | 2014-07-23 | 国立大学法人京都大学 | 効率的な核初期化方法 |
| CA2695590C (en) | 2008-06-27 | 2018-01-09 | Kyoto University | Method of efficiently establishing induced pluripotent stem cells |
| US20100076183A1 (en) | 2008-09-22 | 2010-03-25 | Dellinger Douglas J | Protected monomer and method of final deprotection for rna synthesis |
| KR101774206B1 (ko) | 2009-08-07 | 2017-09-04 | 고쿠리츠 다이가쿠 호진 교토 다이가쿠 | 유도된 다능성 줄기 세포의 효율적인 확립 방법 |
| JP5682043B2 (ja) | 2009-09-02 | 2015-03-11 | 国立大学法人京都大学 | 安全な多能性幹細胞の選択方法 |
| US9585920B2 (en) | 2011-02-04 | 2017-03-07 | Katherine Rose Kovarik | Method and system for treating cancer cachexia |
| US9528124B2 (en) | 2013-08-27 | 2016-12-27 | Recombinetics, Inc. | Efficient non-meiotic allele introgression |
| GB201122458D0 (en) | 2011-12-30 | 2012-02-08 | Univ Wageningen | Modified cascade ribonucleoproteins and uses thereof |
| RU2650811C2 (ru) | 2012-02-24 | 2018-04-17 | Фред Хатчинсон Кэнсер Рисерч Сентер | Композиции и способы лечения гемоглобинопатии |
| US9637739B2 (en) | 2012-03-20 | 2017-05-02 | Vilnius University | RNA-directed DNA cleavage by the Cas9-crRNA complex |
| WO2013141680A1 (en) | 2012-03-20 | 2013-09-26 | Vilnius University | RNA-DIRECTED DNA CLEAVAGE BY THE Cas9-crRNA COMPLEX |
| US9512163B2 (en) | 2012-05-21 | 2016-12-06 | Agilent Technologies, Inc. | Compositions and methods for conjugating oligonucleotides |
| EP3241902B1 (en) | 2012-05-25 | 2018-02-28 | The Regents of The University of California | Methods and compositions for rna-directed target dna modification and for rna-directed modulation of transcription |
| HK1207111A1 (en) | 2012-08-03 | 2016-01-22 | 加利福尼亚大学董事会 | Methods and compositions for controlling gene expression by rna processing |
| CA2884162C (en) | 2012-09-07 | 2020-12-29 | Dow Agrosciences Llc | Fad3 performance loci and corresponding target site specific binding proteins capable of inducing targeted breaks |
| UA118090C2 (uk) | 2012-09-07 | 2018-11-26 | ДАУ АГРОСАЙЄНСІЗ ЕлЕлСі | Спосіб інтегрування послідовності нуклеїнової кислоти, що представляє інтерес, у ген fad2 у клітині сої та специфічний для локусу fad2 білок, що зв'язується, здатний індукувати спрямований розрив |
| US20140075593A1 (en) | 2012-09-07 | 2014-03-13 | Dow Agrosciences Llc | Fluorescence activated cell sorting (facs) enrichment to generate plants |
| UA119135C2 (uk) | 2012-09-07 | 2019-05-10 | ДАУ АГРОСАЙЄНСІЗ ЕлЕлСі | Спосіб отримання трансгенної рослини |
| EP4357457B1 (en) | 2012-10-23 | 2024-10-16 | Toolgen Incorporated | Composition for cleaving a target dna comprising a guide rna specific for the target dna and cas protein-encoding nucleic acid or cas protein, and use thereof |
| US20150315576A1 (en) | 2012-11-01 | 2015-11-05 | Massachusetts Institute Of Technology | Genetic device for the controlled destruction of dna |
| WO2014071219A1 (en) | 2012-11-01 | 2014-05-08 | Factor Bioscience Inc. | Methods and products for expressing proteins in cells |
| WO2014089533A2 (en) | 2012-12-06 | 2014-06-12 | Synthetic Genomics, Inc. | Algal mutants having a locked-in high light acclimated phenotype |
| EP3363902B1 (en) | 2012-12-06 | 2019-11-27 | Sigma Aldrich Co. LLC | Crispr-based genome modification and regulation |
| US9447422B2 (en) | 2012-12-06 | 2016-09-20 | Synthetic Genomics, Inc. | Autonomous replication sequences and episomal DNA molecules |
| DK2931897T3 (en) | 2012-12-12 | 2018-02-05 | Broad Inst Inc | CONSTRUCTION, MODIFICATION AND OPTIMIZATION OF SYSTEMS, PROCEDURES AND COMPOSITIONS FOR SEQUENCE MANIPULATION AND THERAPEUTICAL APPLICATIONS |
| AU2013359262C1 (en) | 2012-12-12 | 2021-05-13 | Massachusetts Institute Of Technology | CRISPR-Cas component systems, methods and compositions for sequence manipulation |
| WO2014093718A1 (en) | 2012-12-12 | 2014-06-19 | The Broad Institute, Inc. | Methods, systems, and apparatus for identifying target sequences for cas enzymes or crispr-cas systems for target sequences and conveying results thereof |
| DK2931898T3 (en) | 2012-12-12 | 2016-06-20 | Massachusetts Inst Technology | CONSTRUCTION AND OPTIMIZATION OF SYSTEMS, PROCEDURES AND COMPOSITIONS FOR SEQUENCE MANIPULATION WITH FUNCTIONAL DOMAINS |
| EP2931899A1 (en) | 2012-12-12 | 2015-10-21 | The Broad Institute, Inc. | Functional genomics using crispr-cas systems, compositions, methods, knock out libraries and applications thereof |
| WO2014093694A1 (en) | 2012-12-12 | 2014-06-19 | The Broad Institute, Inc. | Crispr-cas nickase systems, methods and compositions for sequence manipulation in eukaryotes |
| US8697359B1 (en) | 2012-12-12 | 2014-04-15 | The Broad Institute, Inc. | CRISPR-Cas systems and methods for altering expression of gene products |
| CA2894684A1 (en) * | 2012-12-12 | 2014-06-19 | The Broad Institute, Inc. | Engineering and optimization of improved crispr-cas systems, methods and enzyme compositions for sequence manipulation in eukaryotes |
| US9970002B2 (en) | 2012-12-12 | 2018-05-15 | Massachusetts Institute Of Technology | Compositions and methods for functional nucleic acid delivery |
| WO2014093709A1 (en) | 2012-12-12 | 2014-06-19 | The Broad Institute, Inc. | Methods, models, systems, and apparatus for identifying target sequences for cas enzymes or crispr-cas systems for target sequences and conveying results thereof |
| CN105121648B (zh) * | 2012-12-12 | 2021-05-07 | 布罗德研究所有限公司 | 用于序列操纵的系统、方法和优化的指导组合物的工程化 |
| CA2895155C (en) | 2012-12-17 | 2021-07-06 | President And Fellows Of Harvard College | Rna-guided human genome engineering |
| MX374090B (es) | 2013-03-14 | 2025-03-05 | Caribou Biosciences Inc | Composiciones y métodos de ácidos nucleicos dirigidos al ácido nucleico. |
| WO2014159719A1 (en) | 2013-03-14 | 2014-10-02 | Scrips Health | Methods of isolating nucleic acids |
| WO2014153118A1 (en) | 2013-03-14 | 2014-09-25 | The Board Of Trustees Of The Leland Stanford Junior University | Treatment of diseases and conditions associated with dysregulation of mammalian target of rapamycin complex 1 (mtorc1) |
| US20160046959A1 (en) | 2013-03-15 | 2016-02-18 | Carlisle P. Landel | Reproducible method for testis-mediated genetic modification (tgm) and sperm-mediated genetic modification (sgm) |
| US9234213B2 (en) | 2013-03-15 | 2016-01-12 | System Biosciences, Llc | Compositions and methods directed to CRISPR/Cas genomic engineering systems |
| US20140364333A1 (en) | 2013-03-15 | 2014-12-11 | President And Fellows Of Harvard College | Methods for Live Imaging of Cells |
| US9957515B2 (en) | 2013-03-15 | 2018-05-01 | Cibus Us Llc | Methods and compositions for targeted gene modification |
| US11332719B2 (en) | 2013-03-15 | 2022-05-17 | The Broad Institute, Inc. | Recombinant virus and preparations thereof |
| US20140273235A1 (en) | 2013-03-15 | 2014-09-18 | Regents Of The University Of Minnesota | ENGINEERING PLANT GENOMES USING CRISPR/Cas SYSTEMS |
| US20140273230A1 (en) | 2013-03-15 | 2014-09-18 | Sigma-Aldrich Co., Llc | Crispr-based genome modification and regulation |
| US20140349400A1 (en) | 2013-03-15 | 2014-11-27 | Massachusetts Institute Of Technology | Programmable Modification of DNA |
| AU2014227653B2 (en) | 2013-03-15 | 2017-04-20 | The General Hospital Corporation | Using RNA-guided foki nucleases (RFNs) to increase specificity for RNA-guided genome editing |
| JP6576904B2 (ja) | 2013-04-04 | 2019-09-18 | トラスティーズ・オブ・ダートマス・カレッジ | ＨＩＶ−１プロウイルスＤＮＡのｉｎｖｉｖｏ切除のための組成物及び方法 |
| JP2016522679A (ja) | 2013-04-04 | 2016-08-04 | プレジデント アンド フェローズ オブ ハーバード カレッジ | ＣＲＩＳＰＲ／Ｃａｓ系を用いたゲノム編集の治療的使用 |
| SI2986729T1 (sl) | 2013-04-16 | 2019-02-28 | Regeneron Pharmaceuticals, Inc. | Ciljana sprememba genoma podgane |
| WO2014172458A1 (en) | 2013-04-16 | 2014-10-23 | University Of Washington Through Its Center For Commercialization | Activating an alternative pathway for homology-directed repair to stimulate targeted gene correction and genome engineering |
| US20160186208A1 (en) | 2013-04-16 | 2016-06-30 | Whitehead Institute For Biomedical Research | Methods of Mutating, Modifying or Modulating Nucleic Acid in a Cell or Nonhuman Mammal |
| CN105683376A (zh) | 2013-05-15 | 2016-06-15 | 桑格摩生物科学股份有限公司 | 用于治疗遗传病状的方法和组合物 |
| US20160122774A1 (en) | 2013-05-29 | 2016-05-05 | Cellectis | A method for producing precise dna cleavage using cas9 nickase activity |
| US11414695B2 (en) | 2013-05-29 | 2022-08-16 | Agilent Technologies, Inc. | Nucleic acid enrichment using Cas9 |
| US11685935B2 (en) | 2013-05-29 | 2023-06-27 | Cellectis | Compact scaffold of Cas9 in the type II CRISPR system |
| WO2014191128A1 (en) | 2013-05-29 | 2014-12-04 | Cellectis | Methods for engineering t cells for immunotherapy by using rna-guided cas nuclease system |
| US20140356956A1 (en) | 2013-06-04 | 2014-12-04 | President And Fellows Of Harvard College | RNA-Guided Transcriptional Regulation |
| EP4596565A3 (en) | 2013-06-04 | 2025-11-05 | President And Fellows Of Harvard College | Rna-guided transcriptional regulation |
| US20150315252A1 (en) | 2013-06-11 | 2015-11-05 | Clontech Laboratories, Inc. | Protein enriched microvesicles and methods of making and using the same |
| US9982277B2 (en) | 2013-06-11 | 2018-05-29 | The Regents Of The University Of California | Methods and compositions for target DNA modification |
| WO2014204723A1 (en) | 2013-06-17 | 2014-12-24 | The Broad Institute Inc. | Oncogenic models based on delivery and use of the crispr-cas systems, vectors and compositions |
| MX2015017312A (es) | 2013-06-17 | 2017-04-10 | Broad Inst Inc | Suministro y uso de composiciones, vectores y sistemas crispr-cas para la modificación dirigida y terapia hepáticas. |
| KR20160019553A (ko) | 2013-06-17 | 2016-02-19 | 더 브로드 인스티튜트, 인코퍼레이티드 | 유사분열 후 세포의 질병 및 장애를 표적화하고 모델링하기 위한 시스템, 방법 및 조성물의 전달, 유전자 조작 및 최적화 |
| EP3011030B1 (en) | 2013-06-17 | 2023-11-08 | The Broad Institute, Inc. | Optimized crispr-cas double nickase systems, methods and compositions for sequence manipulation |
| WO2014204724A1 (en) | 2013-06-17 | 2014-12-24 | The Broad Institute Inc. | Delivery, engineering and optimization of tandem guide systems, methods and compositions for sequence manipulation |
| JP2016528890A (ja) | 2013-07-09 | 2016-09-23 | プレジデント アンド フェローズ オブ ハーバード カレッジ | ＣＲＩＳＰＲ／Ｃａｓ系を用いるゲノム編集の治療用の使用 |
| JP7120717B2 (ja) | 2013-07-09 | 2022-08-17 | プレジデント アンド フェローズ オブ ハーバード カレッジ | 多重ｒｎａ誘導型ゲノム編集 |
| EP3019005B1 (en) | 2013-07-10 | 2019-02-20 | EffStock, LLC | Mrap2 knockouts |
| WO2015006294A2 (en) | 2013-07-10 | 2015-01-15 | President And Fellows Of Harvard College | Orthogonal cas9 proteins for rna-guided gene regulation and editing |
| SMT202100691T1 (it) * | 2013-07-11 | 2022-01-10 | Modernatx Inc | Composizioni 5 comprendenti polinucleotidi sintetici che codificano proteine correlate a crispr e sgrna sintetici e metodi d'uso |
| US10563225B2 (en) | 2013-07-26 | 2020-02-18 | President And Fellows Of Harvard College | Genome engineering |
| US20150044192A1 (en) | 2013-08-09 | 2015-02-12 | President And Fellows Of Harvard College | Methods for identifying a target site of a cas9 nuclease |
| WO2015021426A1 (en) | 2013-08-09 | 2015-02-12 | Sage Labs, Inc. | A crispr/cas system-based novel fusion protein and its application in genome editing |
| CA3109801C (en) * | 2013-08-22 | 2024-01-09 | Andrew Cigan | Plant genome modification using guide rna/cas endonuclease systems and methods of use |
| WO2015035034A1 (en) | 2013-09-04 | 2015-03-12 | Mice With Horns, Llc | Materials and methods for correcting recessive mutations in animals |
| AU2014316676B2 (en) | 2013-09-04 | 2020-07-23 | Csir | Site-specific nuclease single-cell assay targeting gene regulatory elements to silence gene expression |
| KR102238137B1 (ko) | 2013-09-04 | 2021-04-09 | 다우 아그로사이언시즈 엘엘씨 | 공여자 삽입을 결정하기 위한 작물에서의 신속 표적화 분석 |
| US9340799B2 (en) | 2013-09-06 | 2016-05-17 | President And Fellows Of Harvard College | MRNA-sensing switchable gRNAs |
| US20150071946A1 (en) | 2013-09-06 | 2015-03-12 | The Johns Hopkins University | Tumor-specific retrotransposon insertions |
| US9388430B2 (en) | 2013-09-06 | 2016-07-12 | President And Fellows Of Harvard College | Cas9-recombinase fusion proteins and uses thereof |
| US9526784B2 (en) | 2013-09-06 | 2016-12-27 | President And Fellows Of Harvard College | Delivery system for functional nucleases |
| EP3418379B1 (en) | 2013-09-18 | 2020-12-09 | Kymab Limited | Methods, cells & organisms |
| WO2015040075A1 (en) | 2013-09-18 | 2015-03-26 | Genome Research Limited | Genomic screening methods using rna-guided endonucleases |
| US20150098954A1 (en) | 2013-10-08 | 2015-04-09 | Elwha Llc | Compositions and Methods Related to CRISPR Targeting |
| DE102013111099B4 (de) | 2013-10-08 | 2023-11-30 | Eberhard Karls Universität Tübingen Medizinische Fakultät | Permanente Genkorrektur mittels nukleotidmodifizierter messenger RNA |
| US20160251675A1 (en) | 2013-10-08 | 2016-09-01 | International Rice Research Institute | Drought-Resistant Cereal Grasses and Related Materials and Methods |
| WO2015052231A2 (en) | 2013-10-08 | 2015-04-16 | Technical University Of Denmark | Multiplex editing system |
| MX358066B (es) | 2013-11-04 | 2018-08-03 | Dow Agrosciences Llc | Óptimos loci de soya. |
| KR102269371B1 (ko) | 2013-11-04 | 2021-06-28 | 코르테바 애그리사이언스 엘엘씨 | 최적 메이즈 유전자좌 |
| TWI669395B (zh) | 2013-11-04 | 2019-08-21 | 美商陶氏農業科學公司 | 一種用於基因標定的通用供體系統 |
| UY35814A (es) | 2013-11-04 | 2015-05-29 | Dow Agrosciences Llc | ?lugares óptimos para la soja?. |
| KR102269769B1 (ko) | 2013-11-04 | 2021-06-28 | 코르테바 애그리사이언스 엘엘씨 | 최적 메이즈 유전자좌 |
| AU2014346559B2 (en) | 2013-11-07 | 2020-07-09 | Editas Medicine,Inc. | CRISPR-related methods and compositions with governing gRNAs |
| US11326209B2 (en) | 2013-11-07 | 2022-05-10 | Massachusetts Institute Of Technology | Cell-based genomic recorded accumulative memory |
| WO2015075056A1 (en) | 2013-11-19 | 2015-05-28 | Thermo Fisher Scientific Baltics Uab | Programmable enzymes for isolation of specific dna fragments |
| US10787684B2 (en) | 2013-11-19 | 2020-09-29 | President And Fellows Of Harvard College | Large gene excision and insertion |
| US9074199B1 (en) | 2013-11-19 | 2015-07-07 | President And Fellows Of Harvard College | Mutant Cas9 proteins |
| CN103614415A (zh) * | 2013-11-27 | 2014-03-05 | 苏州同善生物科技有限公司 | 一种基于crispr基因敲除技术建立肥胖症大鼠动物模型的方法 |
| AU2014361781B2 (en) | 2013-12-12 | 2021-04-01 | Massachusetts Institute Of Technology | Delivery, use and therapeutic applications of the CRISPR -Cas systems and compositions for genome editing |
| EP3080259B1 (en) | 2013-12-12 | 2023-02-01 | The Broad Institute, Inc. | Engineering of systems, methods and optimized guide compositions with new architectures for sequence manipulation |
| EP3470089A1 (en) | 2013-12-12 | 2019-04-17 | The Broad Institute Inc. | Delivery, use and therapeutic applications of the crispr-cas systems and compositions for targeting disorders and diseases using particle delivery components |
| US20150165054A1 (en) | 2013-12-12 | 2015-06-18 | President And Fellows Of Harvard College | Methods for correcting caspase-9 point mutations |
| BR112016013207A2 (pt) | 2013-12-12 | 2017-09-26 | Massachusetts Inst Technology | administração, uso e aplicações terapêuticas dos sistemas crispr-cas e composições para o hbv e distúrbios e doenças virais |
| AU2014361834B2 (en) | 2013-12-12 | 2020-10-22 | Massachusetts Institute Of Technology | CRISPR-Cas systems and methods for altering expression of gene products, structural information and inducible modular Cas enzymes |
| MX2016007325A (es) | 2013-12-12 | 2017-07-19 | Broad Inst Inc | Composiciones y metodos de uso de sistemas crispr-cas en desordenes debidos a repeticion de nucleotidos. |
| US9994831B2 (en) | 2013-12-12 | 2018-06-12 | The Regents Of The University Of California | Methods and compositions for modifying a single stranded target nucleic acid |
| JP6793547B2 (ja) | 2013-12-12 | 2020-12-02 | ザ・ブロード・インスティテュート・インコーポレイテッド | 最適化機能ＣＲＩＳＰＲ−Ｃａｓ系による配列操作のための系、方法および組成物 |
| WO2015138510A1 (en) * | 2014-03-10 | 2015-09-17 | Editas Medicine., Inc. | Crispr/cas-related methods and compositions for treating leber's congenital amaurosis 10 (lca10) |
| US11242525B2 (en) * | 2014-03-26 | 2022-02-08 | Editas Medicine, Inc. | CRISPR/CAS-related methods and compositions for treating sickle cell disease |
| EP3149171A1 (en) | 2014-05-30 | 2017-04-05 | The Board of Trustees of The Leland Stanford Junior University | Compositions and methods of delivering treatments for latent viral infections |
| US20150344836A1 (en) | 2014-05-30 | 2015-12-03 | Ohio State Innovation Foundation | Agrobacterium Strains for Plant Transformation and Related Materials and Methods |
| WO2015191693A2 (en) * | 2014-06-10 | 2015-12-17 | Massachusetts Institute Of Technology | Method for gene editing |
| EP3919621A1 (en) | 2014-06-23 | 2021-12-08 | The General Hospital Corporation | Genomewide unbiased identification of dsbs evaluated by sequencing (guide-seq) |
| HUE049405T2 (hu) | 2014-06-23 | 2020-09-28 | Regeneron Pharma | Nukleáz-közvetített DNS-összeállítás |
| EP3164148A4 (en) | 2014-06-25 | 2017-12-13 | Cold Spring Harbor Laboratory | Methods and compositions for inhibiting growth and epithelial to mesenchymal transition (emt) in cancer cells |
| WO2015200555A2 (en) | 2014-06-25 | 2015-12-30 | Caribou Biosciences, Inc. | Rna modification to engineer cas9 activity |
| WO2016019144A2 (en) | 2014-07-30 | 2016-02-04 | Sangamo Biosciences, Inc. | Gene correction of scid-related genes in hematopoietic stem and progenitor cells |
| WO2016022363A2 (en) | 2014-07-30 | 2016-02-11 | President And Fellows Of Harvard College | Cas9 proteins including ligand-dependent inteins |
| ES2730378T3 (es) | 2014-08-27 | 2019-11-11 | Caribou Biosciences Inc | Procedimientos para incrementar la eficiencia de la modificación mediada por Cas9 |
| JP6594955B2 (ja) | 2014-08-27 | 2019-10-23 | ニユー・イングランド・バイオレイブス・インコーポレイテツド | シントン形成 |
| WO2016049024A2 (en) | 2014-09-24 | 2016-03-31 | The Broad Institute Inc. | Delivery, use and therapeutic applications of the crispr-cas systems and compositions for modeling competition of multiple cancer mutations in vivo |
| WO2016049251A1 (en) | 2014-09-24 | 2016-03-31 | The Broad Institute Inc. | Delivery, use and therapeutic applications of the crispr-cas systems and compositions for modeling mutations in leukocytes |
| WO2016049163A2 (en) | 2014-09-24 | 2016-03-31 | The Broad Institute Inc. | Use and production of chd8+/- transgenic animals with behavioral phenotypes characteristic of autism spectrum disorder |
| US11408007B2 (en) | 2014-09-26 | 2022-08-09 | Yale University | Compositions and methods for biocontainment of microorganisms |
| KR102524798B1 (ko) | 2014-09-26 | 2023-04-24 | 필립모리스 프로덕츠 에스.에이. | 니트레이트 동화 경로의 변경을 통한 담배 특이적 니트로소아민의 감소 |
| JP6702951B2 (ja) | 2014-09-26 | 2020-06-03 | オンテラ インコーポレイテッド | 合成プローブのナノ細孔センシングによる標的配列検出 |
| WO2016048891A1 (en) | 2014-09-26 | 2016-03-31 | Pioneer Hi-Bred International, Inc. | Wheat ms1 polynucleotides, polypeptides, and mehtods of use |
| WO2016057951A2 (en) | 2014-10-09 | 2016-04-14 | Life Technologies Corporation | Crispr oligonucleotides and gene editing |
| CN107106615A (zh) | 2014-10-09 | 2017-08-29 | 人类起源公司 | 胎盘来源的贴壁细胞外泌体及其用途 |
| US9816080B2 (en) | 2014-10-31 | 2017-11-14 | President And Fellows Of Harvard College | Delivery of CAS9 via ARRDC1-mediated microvesicles (ARMMs) |
| CN107429246B (zh) | 2014-10-31 | 2021-06-01 | 麻省理工学院 | 用于crispr的大规模并行组合遗传学 |
| WO2016069282A1 (en) | 2014-10-31 | 2016-05-06 | The Trustees Of The University Of Pennsylvania | Altering gene expression in modified t cells and uses thereof |
| US10900034B2 (en) | 2014-12-03 | 2021-01-26 | Agilent Technologies, Inc. | Guide RNA with chemical modifications |
| CN112877327B (zh) * | 2014-12-18 | 2024-11-22 | 综合基因技术公司 | 基于crispr的组合物和使用方法 |
| EP3280803B1 (en) | 2015-04-06 | 2021-05-26 | The Board of Trustees of the Leland Stanford Junior University | Chemically modified guide rnas for crispr/cas-mediated gene regulation |
| WO2017053729A1 (en) | 2015-09-25 | 2017-03-30 | The Board Of Trustees Of The Leland Stanford Junior University | Nuclease-mediated genome editing of primary cells and enrichment thereof |
| WO2017106657A1 (en) | 2015-12-18 | 2017-06-22 | The Broad Institute Inc. | Novel crispr enzymes and systems |
| US11761007B2 (en) | 2015-12-18 | 2023-09-19 | The Scripps Research Institute | Production of unnatural nucleotides using a CRISPR/Cas9 system |
| AU2016370726B2 (en) | 2015-12-18 | 2022-12-08 | Danisco Us Inc. | Methods and compositions for polymerase II (Pol-II) based guide RNA expression |
| EP3708665A1 (en) | 2015-12-18 | 2020-09-16 | Danisco US Inc. | Methods and compositions for t-rna based guide rna expression |
| WO2017106569A1 (en) | 2015-12-18 | 2017-06-22 | The Regents Of The University Of California | Modified site-directed modifying polypeptides and methods of use thereof |
| CN109072218B (zh) | 2015-12-18 | 2023-04-18 | 国立研究开发法人科学技术振兴机构 | 基因修饰非人生物、卵细胞、受精卵以及目的基因的修饰方法 |
| US10767175B2 (en) | 2016-06-08 | 2020-09-08 | Agilent Technologies, Inc. | High specificity genome editing using chemically modified guide RNAs |
-
2016
- 2016-04-05 EP EP16720220.9A patent/EP3280803B1/en active Active
- 2016-04-05 WO PCT/US2016/026028 patent/WO2016164356A1/en not_active Ceased
- 2016-04-05 CA CA2981715A patent/CA2981715A1/en active Pending
- 2016-04-05 ES ES16720220T patent/ES2884838T3/es active Active
- 2016-04-05 CN CN201680032647.XA patent/CN107787367B/zh active Active
- 2016-04-05 KR KR1020177031965A patent/KR102648489B1/ko active Active
- 2016-04-05 JP JP2017552447A patent/JP6873911B2/ja active Active
- 2016-04-05 AU AU2016246450A patent/AU2016246450B2/en active Active
- 2016-04-05 KR KR1020247008357A patent/KR102888521B1/ko active Active
- 2016-04-05 CN CN202111196588.9A patent/CN114231527A/zh active Pending
-
2017
- 2017-10-03 US US15/724,073 patent/US11306309B2/en active Active
-
2022
- 2022-03-14 US US17/694,310 patent/US11535846B2/en active Active
- 2022-03-14 US US17/694,361 patent/US11851652B2/en active Active
- 2022-03-14 US US17/694,336 patent/US20220195426A1/en not_active Abandoned
- 2022-06-17 AU AU2022204254A patent/AU2022204254B2/en active Active
-
2024
- 2024-01-09 US US18/408,504 patent/US20240401034A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018513682A5 (https=) | ||
| JP7698828B2 (ja) | Ｒｎａを編集する方法および組成物 | |
| US20230365962A1 (en) | Targeted rna editing by leveraging endogenous adar using engineered rnas | |
| US10752918B2 (en) | Methods and products for expressing proteins in cells | |
| ES2985812T3 (es) | Edición genómica de precisión de alto rendimiento | |
| JP2022009734A (ja) | タイチン系ミオパチー及び他のタイチノパチーの治療のための材料及び方法 | |
| US11492670B2 (en) | Compositions and methods for targeting cancer-specific sequence variations | |
| JP6997623B2 (ja) | オリゴヌクレオチドを利用して細胞内の核酸を編集するための組成物および方法 | |
| TW202028466A (zh) | 編輯RNAs的方法以及組成物 | |
| US20230101597A1 (en) | Compositions and methods for treating alpha-1 antitrypsin deficiency | |
| JP2021511038A5 (https=) | ||
| JP2019524149A5 (https=) | ||
| JP2016537028A5 (https=) | ||
| CA2968336A1 (en) | Construct for site directed editing of an adenosine nucleotide in target rna | |
| US20240309368A1 (en) | Targeted rna editing by leveraging endogenous adar using engineered rnas | |
| WO2019010091A1 (en) | METHODS AND COMPOSITIONS FOR FACILITATING HOMOLOGOUS RECOMBINATION | |
| Kyriakopoulou et al. | Gene editing innovations and their applications in cardiomyopathy research | |
| Park et al. | Applications of CRISPR technologies to the development of gene and cell therapy | |
| CN117980482A (zh) | Rbm20突变的基因组编辑 | |
| EP4408986A1 (en) | Compositions and methods for treating hepatitis b virus infection | |
| WO2023046086A1 (zh) | 一种碱基编辑系统及其应用 | |
| WO2021182517A1 (ja) | －１フレームシフトを誘導するための１本鎖核酸分子及び組成物 | |
| US20240325454A1 (en) | Genomic editing of rbm20 mutations | |
| Liu | The use of new CRISPR tools in cardiovascular research and medicine | |
| CN120624447A (zh) | 一种靶向前激肽释放酶的gRNA、重组载体、RNA递送系统、基因编辑系统、重组细胞及其应用 |